A unique experience with human pre-immune (12 weeks) and hypo-immune (16 weeks) fetal thymus transplant in a vascular subcutaneous axillary fold in patients with advanced cancer: A report of two cases

Background: The successful development of fetal cell/tissue transplantation in adults has resulted in the possibility of eventual therapeutic solutions with a variety of intractable diseases. Umbilical cord whole blood transplantation appears to be safe in the adult system. In severe forms of DiGeorge Syndrome, cultured thymus transplant can help in the reconstitution of the immune condition of the host. Successful fetal tissue transplant in adults has raised the hope of future effective gene transplant and its manipulation prospects to combat many diseases including hemopathies, inborn errors of metabolism, immunodeficiencies and even cancer and AIDS.

Materials and method: Two cases of advanced cancer were treated with fetal (pre-immune 12 weeks and hypo-immune 16 weeks) thymus transplants in subcutaneous vascular axillary folds, which were removed after one month. Thymuses were collected from consenting mothers undergoing hysterotomy and ligation.

Results and analysis: Patient I was suffering from non-Hodgkins lymphoma (Ann Arbor Stage IV) and was receiving cyclophosphomide, doxorubicin, vincristine and prednisolone after a course of radiotherapy; she developed leucopenia (2.400/cmm), which improved after receiving a 16-week human fetal thymic graft. The leucopenia was eventually over-corrected and the leucocyte count reached 44,000/cmm within a month, which was reversed after the thymus was taken out. Histology of the excised thymic graft showed growth and proliferation without any graft vs. host (GVH) reaction. Patient 2 was suffering from breast duct carcinoma (T4, N2, M0,) with estrogen, progesterone, and epidermal growth factor negative status, and was treated with modified radical mastectomy and axillary clearance followed by chemotherapy with cyclophosphomide, methotrexate and 5-fluorouracil for six cycles. She also received a 12-week-old human fetal thymus at the contra-lateral axilla which was removed after one month. In this case the peripheral leucocyte count did not show appreciable variation as in the first case. However, histology of the excised thymic graft showed growth and proliferation with an appearance of Hassel's corpuscles.

Conclusion: Pre-immune and hypo-immune human fetal thymic transplant is not rejected in patients suffering from advanced cancer within one month (observation period). Thymic lymphocyte shedding in the correction of leucopenia in the background of non-Hodgkin's lymphoma may have many therapeutic implications.

Human pre-immune (12 weeks) and hypo-immune (16 weeks) fetal thymus transplant can grow and proliferate in advanced cancer patients.

[1] Bhattacharya N., Mukherjee K. L., Chettri M. K., Banerjee T., Mani U., Bhattacharya S.: "A study report of 174 units of placental umbilical cord whole blood safe transfusion in 62 patients as a rich source of fetal haemoglobin supply in different indications of blood transfusion". Clinical and Experimental Obstetrics and Gynecology, 2001, 28(1), 47.

[2] Markert M. L., Boeck A., Hale L. P. et al.:'Transplantation of thymus tissue in complete DiGeorge syndrome". N. Engl. J. Med., 1999 Oct. 14, 341(16), 1180.

[3] Markert M. L., Hummel D.S., Rosenblatt H. M. et al.: "Complete DiGeorge syndrome; persistence of profound immunodeficiency" J. Pediatr., 1998儿n., 132(1), 15.

[4] Hanahan D.: "Peripheral antigen expressing cells in thym,c medulla: Factors in self-tolerance and autoimmunity". Curr. Opin. Immunol., 1998 Dec., 10(6), 656.

[5] Hong R., Moore A. L.: "Organ culture for thymus transplantation". Transplantation, 1996 Feb. 15, 61(3), 444.

[6] Atkinson K,, Storb R., Ochs H. D. et al.:'Thymus transplantation after allogenic bone marrow graft to prevent chronic graft vs. host disease in humans". Transplantation, 1982 Feb., 33(2), 168.

[7] Hong R.: "Present and future status of thymus transplantation" Ann. Clin. Res., 1981, 13(4-5), 350.

[8] PahwaS., Pahwa R.. Tncefy G. et al.: "Future of immunologic reconstitution in a patient with DiGeorge syndrome after fetal thymus transplantation". Clin. lmmunol. lmmunopathol., 1979 Sept., 14(1), 96.

[9] Touraine J. L., Roncarolo M. G., Royo C., Touraine F: "Fetal tissue transplantation, bone marrow transplantation and prospective gene therapy in severe immunodeficiencies and enzyme deficiencies". Thymus, 1987, 10(1), 75.

[10] Hong R.: "Thymus transplantation". Birth. Defects. Orig. Artie Ser., 1983, 19(3), 259.

[11] Dacie J. V., Lewis S. M.: "Practical Hematology". 8th ed., Churchill Livingstone, 1994.

[12] Kay H. E. M.: "Fetal thymus transplants in man". In: "Ontogeny of acquired immunity". A Ciba Foundation Symposium, Elsevier, Excerpta Medica, North Holland, 1972, 249.

[13] Hong R.: "Communication".Jbid.

[14] Miller R. K.: "Fetal drug therapy: Principles and issues". In: Pitkm M. R. and Scott J. R. eds., Clinics in Obstetrics and Gynecology, June 1991, 34(2), 241.

[15] Harrison M. R.: "Fetal surgery". American J. of Obstetrics and Gynecology, 1996, 174(4), 1255.